Gilead, Global Fund to supply HIV prevention drug to two million people
HQ Team July 10, 2025: Gilead Sciences Inc. and the Global Fund have signed a pact to supply an HIV prevention drug at.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team July 10, 2025: Gilead Sciences Inc. and the Global Fund have signed a pact to supply an HIV prevention drug at.
The European Commission has granted marketing approval for Biogen Inc.’s therapy for the treatment of a form of amyotrophic lateral sclerosis.
HQ Team February 24, 2024: Biogen Inc., a US biotechnology company, has got marketing authorisation from the European medicines regulator for its drug.